N/A N=2 F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
Brain Metastases From Breast Cancer
Primary: Number of Participants With Adverse Events — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P
Pharmacokinetics
Primary: Plasma Nicotine Concentration-time Profile — 0.751; 0.336; 0.205; 0.478 ng/mL
Phase 2 N=46 Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Peripheral Artery Disease (PAD); Intermittent Claudication
Primary: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths — 18; 17; 4; 4 Participants
N/A N=220 Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient
Asthma
Primary: Number of Subjects Hospitalized — 22; 15 Participants
Phase 2 N=198 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Sickle Cell Disease
Primary: Annual Rate of Sickle Cell-related Pain Crises (SCPC) Per Hodges-Lehmann Median — 1.63; 2.01; 2.98 SCPC per year — p== 0.010
Phase 2 N=22 A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions — 622.8; 867 ug/ml
Phase 2 N=55 Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Leukemia · Lymphoma
Primary: Number of Participants (Incidence) of LTLS (Laboratory Tumor Lysis Syndrome) — 1; 1 Participants
N/A N=100 Trial of Low Residue Diet Versus Clear Liquids Following Elective Colorectal Surgery
Nausea/Vomiting
Primary: Number of Participants Who Experienced Emesis on Post Operative Day 2 — 9; 9 Participants
N/A N=51 Nutrition and Aerobic Exercise in Chronic Stroke
Stroke
Primary: The Change in Total Daily Energy Expenditure — -0.52; 32.86 change in kcal/day
Phase 2 N=318 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Response Rate — 89 percentage of patients
Phase 2 N=81 Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Primary: Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time — 239; 179; 208; 222 ng/mL
N/A N=210 Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?
Parkinson's Disease
Primary: Changes in the Subjects Quality of Life (QOL) — -0.8446; 0.6576 score on a scale — p=0.0272
N/A N=185 Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
Dry Eye Syndromes
Primary: Change From Pre-Application to Post-Application in Eye Dryness Score (EDS) Using a Visual Analog Scale (VAS) — -16.48; -3.12 score on a scale — p=<0.0001
N/A N=20 Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
Dry Eye Syndromes
Primary: Change From Pre-Application to Post-Application in the Ora Calibra Ocular Discomfort Scale (ODS) Score — -1.1; -0.4 score on a scale — p=0.008
N/A N=31 Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
Adenocarcinoma of the Prostate
Primary: Number of Putative Sites of Metastatic Disease as Determined by 18F-DCFPyL PET/CT — 21; 5; 5 Participants